Drugmaker patient assistance rules for 31 drugs, read on their own pages: limits run from $31,920 to $79,800 for one person
Ozempic shows no income figure, Wegovy is not on the list, Farxiga was removed for new patients, and nine rows exclude Medicare outright. Every row is dated and linked to the page it came from.
Of the seven drugs people ask about most, the drugmaker's own page states an income limit for four (Trelegy, Eliquis, Jardiance, Repatha), names none for Ozempic, does not list Wegovy, and has removed Farxiga for new patients; across all 18 rows with a stated one-person limit the figures run from $31,920 to $79,800, a 2.5x spread, and 9 of the 32 rows exclude Medicare patients outright.
Method: every row read in Chrome on the drugmaker's own page or document on 2026-10-29; protocol frozen before the first read. How we built this · the full table · downloadsQuick answer: do the drugmakers publish who qualifies for free medicine?
For the 31 drugs checked at 13 drugmakers, on 2026-10-29:
- 19 of 32 rows carry a stated income rule on the drugmaker's own page or form. Another 3 are listed but give no figure, 9 are not on the drugmaker's list, and 1 could not be read.
- Stated one-person limits run from $31,920 to $79,800, depending far more on the drug than on the company.
- Eligibility is two tests, not one. Insurance decides whether you can apply at all: 9 rows exclude Medicare patients, 8 allow them only with a condition such as a Part D spending threshold or an Extra Help denial, and 2 allow them plainly.
What do the drugmakers say about the seven most asked-about drugs?
These are the drugs that head OmniRx's rows in a sample of AI-search citations: Ozempic, Wegovy, Trelegy, Farxiga, Eliquis, Jardiance and Repatha. Only the aggregate fact is used here; no query text is published. Four of the seven have a stated limit. The other three are the ones most worth knowing about before anyone spends an afternoon on an application.
- Ozempic. Novo Nordisk's page says only that household income must "qualify" and points readers to a third-party site for poverty guidelines. Its product list marks Ozempic as available to uninsured patients only. No percentage or dollar limit appears on the page, the product list or the first page of the application.
- Wegovy. Not on Novo Nordisk's available-products list on the read date. Neither is Rybelsus.
- Farxiga. AstraZeneca's AZ&Me stopped accepting new Farxiga patients on 1 May 2026 because generic versions arrived in April. Enrolled patients are supported to 31 December 2026.
- Jardiance. Boehringer Cares publishes a 250% limit ($39,900 for one person) but, from 15 October 2026, no longer accepts new Medicare Part D or Advantage enrollments for it.
- Eliquis, Repatha, Trelegy. Stated limits of $47,880 for one person at Bristol Myers Squibb, Amgen and (Medicare path) GSK. Amgen requires no insurance coverage at all; Bristol Myers Squibb lets Medicare patients in once they have spent 3% of income on prescriptions.
How many rows came back with a usable answer?
Rows that could not be read stay in the data and are counted, not guessed. A page that blocked reading, or a drug list that sat behind an application flow, is recorded as "not read" rather than filled from another site. Secondary sources such as price sites and news stories are never used as a source.
What are the one-person income limits?
The percentage rule is not the whole story. Lilly Cares sets 300% of the poverty level for Trulicity but 400% for Humalog. Boehringer Cares uses 200% for its Respimat inhalers and 250% for everything else. Merck's Januvia line is $63,840 while Keytruda is $79,800. And Bristol Myers Squibb states no income cap for its cancer medicines at all.
| Drugmaker | Lower limit | Higher limit | Gap |
|---|---|---|---|
| Lilly Cares | Trulicity $47,880 (300%) | Humalog $63,840 (400%) | 1.33x |
| Boehringer Cares | Spiriva Respimat $31,920 (200%) | Jardiance $39,900 (250%) | 1.25x |
| Merck | Januvia $63,840 | Keytruda $79,800 | 1.25x |
| Bristol Myers Squibb | Eliquis $47,880 | Opdivo no cap stated | no ratio |
6 of the 18 stated limits sit above $55,000, and 12 sit below it. That count is only about income for a household of one; it says nothing about whether the program is open to someone with insurance.
Who does the insurance rule shut out?
Most programs are built for the uninsured. Amgen, Merck and Novo Nordisk's Ozempic exclude people with Medicare. Boehringer Cares closed primary-care products to new Medicare enrollments on 15 October 2026. Others admit Medicare patients under conditions: Bristol Myers Squibb wants 3% of yearly income already spent on prescriptions, GSK wants $600 spent in the calendar year, and Johnson & Johnson, AstraZeneca and Novo Nordisk ask for proof of a Low Income Subsidy denial where relevant. Lilly Cares states plainly that Medicare Part D patients may apply, except those on full Extra Help, Medicaid or VA benefits.
Which rules changed recently?
| Effective | What changed | Source |
|---|---|---|
| 2026-05-01 | Farxiga removed from AstraZeneca AZ&Me for new patients | AstraZeneca |
| 2026-10-15 | Boehringer Cares stopped accepting new Medicare Part D or Advantage enrollments for primary care products (including Jardiance, Tradjenta, Spiriva Respimat) | Boehringer Ingelheim |
| 2026-09-11 | Boehringer Cares Ofev no longer available through the program | Boehringer Ingelheim |
| read 2026-10-29 | Lilly Cares again accepts new Trulicity applications without a medical exception request | Lilly |
The dated rows matter because assistance rules move faster than most articles about them. The dataset is a dated snapshot with a stable identifier; later versions will carry the changes. Version 1.1 (30 October 2026) read three rows that version 1.0 held as not read: Symbicort and Brilinta are not on the AZ&Me list, and Humira is on the AbbVie list. The version history is in data.json and the README.
What does this mean, by reader?
- If you are uninsured and take Eliquis, Repatha, Trelegy or JardianceThe maker publishes a limit you can check against your household today. Use the one for your household size, from the drugmaker's own page, and call the program to confirm before you collect documents.
- If you take OzempicNovo Nordisk publishes no income figure and limits Ozempic to uninsured patients. Ask the program for the limit in dollars for your household size before you apply, and ask whether your insurance status qualifies.
- If you take Wegovy, Mounjaro or ZepboundNone is on the drugmaker's patient assistance list on the read date. Look at the maker's savings and direct-purchase programs instead; those are different programs with different rules.
- If you have Medicare Part DCheck the insurance rule first: a program can be open on income and closed on coverage. Apply for Extra Help where the program asks for a denial letter.
- If you write about or build tools for thisUse the rows with their read dates and source links, treat "not read" as unknown, and keep the date visible; a figure without a read date is already out of date.
The full table: 32 rows
Each row links to the page or document it was read from. The CSV carries every column, including household sizes two to four, the per-extra-person amount and the conditions in the drugmaker's own terms.
| Drug | Drugmaker (source page) | One-person limit | Medicare | Insurance rule |
|---|---|---|---|---|
| Anoro Ellipta | GSK | $47,880 | allowed with conditions | uninsured or underinsured |
| Breo Ellipta | GSK | $47,880 | allowed with conditions | uninsured or underinsured |
| Brilinta | AstraZeneca | not on list | not published | not published |
| Dupixent | Sanofi | not on list | not published | not published |
| Eliquis | Bristol Myers Squibb | $47,880 | allowed with conditions | uninsured or underinsured |
| Eliquis | Pfizer | not read | not published | not published |
| Enbrel | Amgen | $47,880 | excluded | uninsured only |
| Entresto | Novartis | not on list | not published | not published |
| Farxiga | AstraZeneca | not on list | not published | not published |
| Humalog | Lilly | $63,840 (400% FPL) | allowed | uninsured or underinsured |
| Humira | AbbVie | $63,840 | not published | uninsured or underinsured |
| Januvia | Merck | $63,840 | excluded | uninsured only |
| Jardiance | Boehringer Ingelheim | $39,900 (250% FPL) | excluded | uninsured only |
| Keytruda | Merck | $79,800 | excluded | uninsured only |
| Lantus | Sanofi | $63,840 (400% FPL) | not published | uninsured or underinsured |
| Mounjaro | Lilly | not on list | not published | not published |
| NovoLog | Novo Nordisk | no figure | allowed with conditions | uninsured or underinsured |
| Opdivo | Bristol Myers Squibb | no cap stated | allowed with conditions | uninsured or underinsured |
| Otezla | Amgen | $47,880 | excluded | uninsured only |
| Ozempic | Novo Nordisk | no figure | excluded | uninsured only |
| Repatha | Amgen | $47,880 | excluded | uninsured only |
| Rybelsus | Novo Nordisk | not on list | not published | not published |
| Skyrizi | AbbVie | $63,840 | not published | uninsured or underinsured |
| Spiriva Respimat | Boehringer Ingelheim | $31,920 (200% FPL) | excluded | uninsured only |
| Symbicort | AstraZeneca | not on list | not published | not published |
| Tradjenta | Boehringer Ingelheim | $39,900 (250% FPL) | excluded | uninsured only |
| Trelegy Ellipta | GSK | $47,880 | allowed with conditions | uninsured or underinsured |
| Tresiba | Novo Nordisk | no figure | allowed with conditions | uninsured or underinsured |
| Trulicity | Lilly | $47,880 (300% FPL) | allowed | uninsured or underinsured |
| Wegovy | Novo Nordisk | not on list | not published | not published |
| Xarelto | Johnson & Johnson | $46,950 (300% FPL) | allowed with conditions | uninsured or underinsured |
| Zepbound | Lilly | not on list | not published | not published |
How was this built, and what is it not?
- Frozen protocol. The drug set, drugmakers, field codes and rules were written down and hashed before the first page was read (SHA-256 519cbab87e85037d…). One amendment was made after the first read: a code for BMS's "no cap for cancer medicines" rule, and a field recording how each row was read. It is published with the data.
- Primary pages only. Every row was read in Chrome on the drugmaker's own page or document on 2026-10-29. PDFs with no text layer were read as screenshots. Nothing was taken from this site's earlier articles or from a secondary site.
- Recomputed. Every stated limit was recomputed from the HHS 2026 poverty guideline ($15,960 for one person, $5,680 for each extra). 17 of 18 recompute exactly. The exception is Johnson & Johnson's Xarelto table, labelled 2026 but equal to 300% of the 2025 guideline, which is 1.94% below 300% of the 2026 figure.
- Not an eligibility decision. This records published rules as read on a date. It does not say whether any person qualifies, and it is not medical or financial advice. No forms were submitted and no personal data was entered anywhere.
- What it leaves out. 1 row could not be read (Pfizer's Eliquis listing, which sits behind an application flow), GSK publishes no income figure for uninsured patients on the pages read, Alaska and Hawaii limits are not in the one-person column, and Pfizer's full medicine list was not opened. Version 2 will re-read every row.
What did this dataset correct, and what did we get wrong?
Reading the drugmakers' own pages showed that some OmniRx pages had said more than the sources support. Each is corrected on the site and listed here with the date, so a reader can see what changed and why.
- Novo Nordisk (29 October 2026). OmniRx pages gave 400% of the poverty level for most Novo Nordisk medicines and 200% for Ozempic. Novo Nordisk's own pages state no figure, so both were withdrawn, along with a Medicare 150% exception for Ozempic that Novo Nordisk's product list does not support.
- AbbVie (29 October 2026). Our income comparison said AbbVie publishes no figure. Its income page states $63,840 for one person, 400% of the 2026 guideline. Corrected.
- Boehringer Ingelheim (29 October 2026). We said it publishes no figure. Its eligibility document states 250% ($39,900 for one person), or 200% for the Respimat inhalers, and shows that new Medicare Part D enrollments for its primary care medicines closed on 15 October 2026. Corrected.
- Drug lists (30 October 2026). Our database listed Dupixent, Aubagio, Kevzara, Praluent and Sarclisa under Sanofi Patient Connection, Breyanzi under Bristol Myers Squibb and Viekira Pak under AbbVie. None is on that drugmaker's own list. Removed; free Dupixent goes through DUPIXENT MyWay.
- This dataset, version 1.1 (30 October 2026). Version 1.0 held Humira as not read because we had opened only AbbVie's returning-patient list. Its full list includes Humira. That was our error, and version 1.1 fixes it.
Download the data
- data.json (everything: rows, checks, headlines, protocol hash)
- rows.csv (the 32 rows)
- household_scaling.csv (limits for household sizes 1 to 8, computed from the guideline)
- evidence-log.jsonl (what was read, where, and when)
- protocol.json (the frozen protocol)
OmniRx (2026). Patient Assistance Program Eligibility by Drug 2026: What Each Drugmaker Publishes, Read on the Sponsor's Own Page (version 1.1). https://doi.org/10.5281/zenodo.23812709. CC BY 4.0.
See also the income limits compared article and the patient assistance finder; the finder works from the same kind of published limits.
Frequently asked questions
Does Novo Nordisk publish an income limit for Ozempic?
Not on the pages read on 29 October 2026. Its patient assistance page says only that household income must qualify and refers readers to a third-party site for poverty guidelines, and its product list marks Ozempic as available to uninsured patients only. Call the program for the dollar limit for your household size.
Is there free-medicine assistance for Wegovy, Mounjaro or Zepbound?
Not through the drugmakers' patient assistance lists read on 29 October 2026: Wegovy is not on Novo Nordisk's available-products list, and Mounjaro and Zepbound are not on the Lilly Cares list. The makers run separate savings and direct-purchase programs with different rules.
Can I still get free Farxiga?
Only if you were already enrolled. AstraZeneca's AZ&Me stopped accepting new Farxiga patients on 1 May 2026 because generic versions became available, and supports enrolled patients to 31 December 2026.
Can Medicare patients use drugmaker assistance programs?
It depends on the program and the drug. In this dataset 9 rows exclude Medicare patients, 8 allow them with a condition such as a spending threshold or an Extra Help denial, and 2 allow them plainly. Boehringer Cares closed new Medicare enrollments for its primary-care products on 15 October 2026.
What does the one-person limit mean?
It is the household income at or below which a single applicant meets the income test, as the drugmaker states it. Larger households have higher limits, shown in the CSV and in the household scaling file. Income is only one test; insurance and other rules also apply.
How current is this data?
Every row was read on 29 October 2026, and each row carries its own read date and source link. Assistance rules change often, so check the drugmaker's page before relying on a figure, and see the dated changes table for what moved recently.
The bottom line
Read the rule for your own drug on the drugmaker's page, in dollars, for your household size, and read the insurance rule before the income rule. Of the seven drugs people ask about most, four have a stated limit, one gives none, one is not listed and one has closed to new patients. The data here is dated 2026-10-29; treat anything older as a lead, not an answer.
Sources
- Novo Nordisk. Novo Nordisk Patient Assistance Program: Ozempic, Wegovy, Rybelsus. novocare.com checked 2026-10-29
- Novo Nordisk. Novo Nordisk Patient Assistance Program: Tresiba, NovoLog. novocare.com checked 2026-10-29
- GSK. GSK Patient Assistance Program: Trelegy Ellipta, Anoro Ellipta, Breo Ellipta. gskpaf.org checked 2026-10-29
- AstraZeneca. AZ&Me Prescription Savings Program: Farxiga. azandmeapp.com checked 2026-10-29
- AstraZeneca. AZ&Me Prescription Savings Program: Symbicort, Brilinta. azandmeapp.com checked 2026-10-30
- Bristol Myers Squibb. Bristol Myers Squibb Patient Assistance Foundation: Eliquis, Opdivo. bmspaf.org checked 2026-10-29
- Pfizer. Pfizer RxPathways Patient Assistance Program: program-wide rule. pfizerrxpathways.com checked 2026-10-29
- Boehringer Ingelheim. Boehringer Cares Patient Assistance Program: Jardiance, Tradjenta, Spiriva Respimat. boehringer-ingelheim.com checked 2026-10-29
- Amgen. Amgen Safety Net Foundation: Repatha. amgensafetynetfoundation.com checked 2026-10-29
- Amgen. Amgen Safety Net Foundation: Otezla. amgensafetynetfoundation.com checked 2026-10-29
- Amgen. Amgen Safety Net Foundation: Enbrel. amgensafetynetfoundation.com checked 2026-10-29
- Lilly. Lilly Cares Foundation Patient Assistance Program: Mounjaro, Zepbound. lillycares.com checked 2026-10-29
- Lilly. Lilly Cares Foundation Patient Assistance Program: Trulicity, Humalog. lillycares.com checked 2026-10-29
- Johnson & Johnson. Johnson & Johnson Patient Assistance Program: Xarelto. asset.jnjwithme.com checked 2026-10-29
- Merck. Merck Patient Assistance Program: Januvia. merckhelps.com checked 2026-10-29
- Merck. Merck Patient Assistance Program: Keytruda. merckhelps.com checked 2026-10-29
- Sanofi. Sanofi Patient Connection (Patient Assistance Connection): Dupixent. sanofipatientconnection.com checked 2026-10-29
- Sanofi. Sanofi Patient Connection (Patient Assistance Connection): Lantus. sanofipatientconnection.com checked 2026-10-29
- Novartis. Novartis Patient Assistance Foundation: Entresto. pap.novartis.com checked 2026-10-29
- AbbVie. myAbbVie Assist: Skyrizi, Humira. abbvie.com checked 2026-10-30
- U.S. Department of Health and Human Services (ASPE). 2026 Poverty Guidelines. aspe.hhs.gov checked 2026-10-29
- Novo Nordisk. Patient Assistance Program application. novocare.com (PDF) checked 2026-10-29
- Boehringer Ingelheim. Important program changes (Medicare Part D and product removals). boehringer-ingelheim.com (PDF) checked 2026-10-29